Company Description
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies to treat cancer and infectious diseases in Germany.
The company develops BNT111, which is in Phase 2 clinical trial for advance melanoma; BNT113, which is in Phase 2 clinical trial to treat head and neck squamous cell carcinoma; BNT116, which is in Phase I clinical trial for non-small cell lung cancer; BNT142, which is in phase 1/2 clinical trial for multiple solid tumors; BNT151, which is in phase 1/2 clinical trial for solid tumors; BNT152+BNT153, which is in phase 1 clinical trial for solid tumors; and BNT122/RO7198457, which is in Phase 2 clinical trial to treat adjuvant high-risk muscle-invasive urothelial carcinoma, colorectal cancer, pancreatic ductal adenocarcinoma, advance melanoma, as well as in phase 1a/1b clinical trial for advanced/metastatic solid tumors.
It also develops BNT211, which is in phase 1 clinical trial to treat CLDN6+ solid tumors; BNT221, phase 1 clinical trial for the treatment of cancer; BNT311/GEN1046 (acasunlimab), which is in phase 3 clinical trial for solid tumors; BNT312/GEN1042, which is in phase 1/2 and 1 clinical trial to treat solid tumors; BNT314/GEN1059, which is in Phase 1/2 clinical trial for advanced or metastatic solid tumors; BNT315/GEN1055, which is in phase 1/2 clinical trial for advanced solid tumors; BNT317, which is in phase 1 clinical trial for advanced solid tumors; BNT327, which is in phase 1/2, 2, and 3 clinical trial to treat small cell lung cancer, advanced/metastatic tnbc, neuroendocrine neoplasm, malignant mesothelioma, EGFR-mutant non-squamous, hepatocellular carcinoma, and advanced solid tumors; and BNT316/ONC-392, which is in phase 1/2, 2, and 3 clinical trial to treat metastatic, non-small cell lung cancer, platinum-resistant ovarian cancer, metastatic castration resistant prostate cancer, and advanced or metastatic solid tumor.
BioNTech SE was incorporated in 2008 and is headquartered in Mainz, Germany.
| Country | Germany |
| Founded | 2008 |
| IPO Date | Oct 10, 2019 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 6,772 |
| CEO | Ugur Sahin |
Contact Details
Address: An der Goldgrube 12 Mainz, 55131 Germany | |
| Phone | 49 6131 9084 |
| Website | biontech.de |
Stock Details
| Ticker Symbol | BNTX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | EUR |
| IPO Price | $15.00 |
| CIK Code | 0001776985 |
| CUSIP Number | 09075V102 |
| ISIN Number | US09075V1026 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Ugur Sahin M.D. | Co-Founder, Chief Executive Officer and Chair of the Management Board |
| Dr. Ozlem Tureci M.D. | Co-Founder, Chief Medical Officer and Member of Management Board |
| Dr. Sierk Poetting Ph.D. | MD, Chief Operating Officer and Member of Management Board |
| Dr. James Timothy Patrick Ryan Ph.D. | Chief Legal and Business Officer and Member of the Management Board |
| Annemarie Hanekamp | Chief Commercial Officer and Member of Management Board |
| Ramon Zapata-Gomez | Chief Financial Officer and Member of Management Board |
| Lisa Birringer | Senior Vice President of Global Financial Reporting and Accounting |
| Beate Berns | Senior Vice President of Global Human Resources |
| Dr. Oliver Henning Ph.D. | Senior Vice President of Operations |
| Dr. Sebastian Kreiter M.D. | Senior Vice President of Immunotherapy and Preclinical Research |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 3, 2025 | 6-K | Report of foreign issuer |
| Nov 3, 2025 | 6-K | Report of foreign issuer |
| Oct 22, 2025 | 6-K | Report of foreign issuer |
| Oct 21, 2025 | F-4/A | Filing |
| Oct 1, 2025 | 6-K | Report of foreign issuer |
| Sep 8, 2025 | 6-K | Report of foreign issuer |
| Sep 8, 2025 | F-4/A | Filing |
| Sep 8, 2025 | 6-K | Report of foreign issuer |
| Sep 5, 2025 | 144 | Filing |
| Sep 5, 2025 | 6-K | Report of foreign issuer |